Cartalax is a short bioregulatory tripeptide derived from cartilage tissue that promotes chondrocyte activity, supports cartilage maintenance, and is studied as part of anti-aging musculoskeletal protocols developed at the St. Petersburg Institute of Bioregulation.
This peptide profile is for research and educational purposes only. Not intended for human use or self-administration.
Overview
Cartalax (Ala-Glu-Asp) is a tripeptide developed by the St. Petersburg Institute of Bioregulation and Gerontology as part of a systematic program to identify tissue-specific short-peptide bioregulators. The methodology behind Cartalax and related peptides (Pinealon, Cortagen, Vilon, etc.) is based on the idea that short peptides derived from specific tissues act as endogenous regulators of gene expression in those same tissues — providing a targeted, tissue-selective regulatory signal that declines with aging. Cartalax targets cartilaginous tissue and is studied for its role in maintaining chondrocyte function, supporting proteoglycan synthesis, and slowing the age-related degradation of joint cartilage.
Mechanism of Action
Cartalax, like other short bioregulatory peptides from the Khavinson group, is believed to act via interaction with chromatin — specifically binding to histone proteins and modulating gene promoter accessibility for genes involved in cell proliferation, differentiation, and tissue-specific protein synthesis. In chondrocytes (cartilage cells), this is thought to maintain or restore the expression of collagen type II, aggrecan, and other structural proteoglycans that deteriorate in osteoarthritis and age-related cartilage loss. The peptide acts as an epigenetic regulator rather than a direct receptor agonist — a mechanism that has been proposed to explain the broad but gentle tissue-maintenance effects seen across this class of peptides.
Key Research
Cartalax was developed and studied primarily at the St. Petersburg Institute of Bioregulation and Gerontology under Prof. Vladimir Khavinson. Published Russian-language research documents protective effects on cartilage tissue in animal aging models, with improved chondrocyte proliferation and reduced articular cartilage degradation in aged rodents. Studies in combination with Vilon and other bioregulatory peptides showed synergistic joint protection effects. The underlying chromatin-binding mechanism has been supported by molecular studies from the same group. Peer review outside of the originating institution is limited; independent replication of findings has not been widely published in Western literature.
100–200 mcg subcutaneously daily or every other day
Half-Life
~30–60 minutes
Cartalax is used at 100–200 mcg subcutaneously daily or every other day for 10–20 day cycles, typically repeated 2–3 times per year. It can be combined with other tissue-specific bioregulatory peptides and is often used alongside BPC-157 or TB-500 for musculoskeletal protocols. Some protocols use it orally (sublingual), though injectable use is more common in research contexts. The low doses and peptide's small size make it practical and well tolerated.
Joint Health Protocol: Cartalax 100 mcg SC daily for 10 days, repeated 3 times per year, combined with BPC-157 250 mcg daily for the same periods. For active joint repair: add TB-500 2.5 mg SC twice weekly during the Cartalax cycle. Anti-Aging Musculoskeletal Stack: combine with Pinealon (for CNS), Vilon (for immune), and GHK-Cu (for connective tissue) as a comprehensive bioregulatory peptide protocol.
Reported Side Effects
Side effects summarized from animal studies and researcher community observations. Educational purposes only — not medical advice.
Cartalax has an excellent safety profile based on available research. No significant adverse events have been documented. At the low doses used in research (nanogram to low-microgram range), systemic effects are minimal. Mild injection site redness may occur. Because the mechanism is epigenetic regulation rather than receptor agonism, there is no dependency, no receptor desensitization, and no rebound effect upon discontinuation. Suitable for elderly individuals and long-term cyclical use.
Storage & Handling
Store lyophilized Cartalax at 2–8°C, protected from light. Stable for up to 12 months. Reconstitute with bacteriostatic or sterile water. Store reconstituted solution at 2–8°C and use within 14–21 days. As a very small tripeptide, it is relatively stable in solution compared to larger peptides.
Age Verification Required
This site contains information about research peptides intended for adults 21 and older. By continuing you confirm you are of legal age in your jurisdiction.
By confirming below, you agree that you are at least 21 years of age and legally able to access this content in your jurisdiction.
Access Restricted
We're sorry, but you must be at least 21 years of age to access this site. This content contains research information intended for adults only.
Research Disclaimer
RESEARCH USE ONLY: All information, tools, and resources on Peptide Oracle are for educational and research purposes only.
Not Medical Advice: Nothing on this website constitutes medical advice, diagnosis, or treatment. This site does not replace professional medical consultation.
Not for Human Consumption: Peptides discussed are for laboratory and research purposes only. They are not approved for human use, consumption, or self-administration.
No Therapeutic Claims: We make no claims regarding the safety, efficacy, or therapeutic benefits of any peptides or compounds discussed.
Legal Compliance: You are responsible for compliance with all applicable local, state, and federal laws regarding peptide research and acquisition.
Limitation of Liability: Peptide Oracle assumes no liability for any damages resulting from use of information provided on this site.
Saved for 30 days. Reset by clearing browser data.
We use cookies to improve your experience and analyse site usage. By clicking Accept All you consent to our use of cookies. Cookie Policy
